Drugmakers push into radio pharmaceuticals
Dolgin, E. Drugmakers go nuclear, continuing push into radiopharmaceuticals. Nat Biotechnol 39, 647–649 [...]
Asco 2021 justifies Novartis’s radioligand Vision
Evaluate Vantage, Jacob Plieth, June 3, 2021 177Lu-PSMA-617 significantly improves [...]
Theranostics: Reimagining the standard of care
HealthCare Business News magazine, June 2021, Tiffany Olson It may [...]
EANM position paper on the role of radiobiology in nuclear medicine
Aerts, A., Eberlein, U., Holm, S. et al. EANM position [...]
Travel cards could help radiopharma patients avoid delays
April 29, 2020 -- Patients who undergo radiation treatment with lutetium-177 [...]
PSMA theranostic Lu-177-PSMA-617 approaches prime time in mCRPC
Urology Times Journal, Jason M. Broderick - April 15, 2021 [...]
Noble Registry – iPSMA SPECT Imaging for Prostate Cancer
BRUSSELS, Belgium and MELBOURNE, Australia, 20th of April 2021 – [...]
Doctor, What is Neuroendocrine Cancer?
Waiting for a download is frustrating. Imagine waiting 5+ years [...]
Seeing Cancer Cells, Killing Cancer Cells
Using molecules to safely carry radioactive materials inside the human [...]
Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC
225Ac-PSMA RLT is an efficacious and safe treatment option for [...]